You searched for "legislation"
Exploring the potential of neurodegenerative disease screening within age-related eye disease research
The authors recruited healthy controls aged between 60 and 75-years-old, previously enrolled into a registry as patients following cataract surgery without age-related macular degeneration (AMD). Exclusion criteria included dense cataract, retinal disease, ocular inflammatory disease, moderate glaucoma, optic neuropathy, cancer,...Unravelling ocular motility
Ocular motility can often be a slightly abstract concept during the earlier years of ophthalmology training. A large variance on what embodies normality; mythical concepts like fusion and binocular vision, examination techniques that can be fiddly, and complex neuroanatomy all...Turn up anytime
When I was starting off in ophthalmology my then boss had a standard spiel after completing a cataract case. It did not vary and I do not recall an instance of it not taking place. “The operation went well and...The results of the last survey Oct20
The point of this series is to find variations in practice and to raise them to you, the readership, so you can review and reflect upon them. I am aware there is not always a ‘correct’ way of doing things,...
Developments in Ophthalmology: Ophthalmic Radiation Therapy Techniques and Applications
Radiation was discovered by Wilhelm Roentgen in 1895, and since then has been used to treat a variety of cancers. Its therapeutic properties have been widely used for ocular and periocular tumours and inflammatory disease, but the present era is...
Vision loss during Eylea treatment for AMD
This report investigated patients who lost more than two lines of vision despite periodic injections of aflibercept and explored the factors associated with vision loss. One hundred and ninety-six eyes were included in this study over a two year period....
Outcomes of ‘treat and extend’ for neovascular AMD
The authors report on 24-month outcomes of anti-vascular endothelial growth factor (anti-VEGF) therapy using a ‘treat and extend’ regime for treatment-naïve neovascular age-related macular degeneration (nAMD). Data for this study was collected from the Fight Retinal Blindness observational registry based...
Aqueous humour cytokine levels in PCV and nAMD
This study looks into the possible roles of various cytokines or growth factors in the pathogenesis of exudative age-related macular degeneration (AMD) by comparing aqueous levels of 14 cytokines between eyes with polypoidal choroidal vasculopathy (PCV) and those with neovascular...
Exposure to atomic bomb radiation and age-related macular degeneration in later life
This paper is one of the outcomes of the Adult Health Study; a cohort study of the atomic bomb survivors of Hiroshima-Nagasaki in Japan. It investigates the proposed association between pasty radiation exposure early in life and the presence of...
Combined anti-VEGF and PDT for wet AMD
The authors report on a retrospective case series of combined anti-VEGF and photodynamic therapy (PDT) in the treatment of wet age-related macular degeneration (AMD) refractory to anti-VEGF monotherapy alone. The criteria for treatment failure of anti-VEGF monotherapy were persistent subretinal...
Four year outcomes of macular degeneration treated with ranibizumab
The authors report on a retrospective study of neovascular age-related macular degeneration (AMD) patients treated with a variable ranibizumab dosing regimen over a period of four years (from January 2007 to December 2011). A total of 600 treatment naïve eyes...
